Cytiva is the global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. We have a rich heritage tracing back hundreds of years, and a fresh beginning since 2020.
Cytiva launches first formulation system to enable end-to-end clinical and commercial manufacturing of lipid nanoparticle medicines
NanoAssemblr Source: Cytiva NanoAssemblr combines scalable mixing technology to deliver seamless formulation of lipid nanoparticle medicines from clinical development to large-scale commercial manufacturing. Single-use fluid path reduces the risk of cross-contamination, supports efficient changeover between batches and facilitates multi-process workflows to accelerate time to market.
Global biotechnology leader builds on Xcellerex heritage to now offer X-platform bioreactors. X-platform bioreactors can be used for monoclonal antibodies (mAbs), protein-based drugs which continue to give rise to new treatments, as well as manufacturing cell and gene therapies and viral vectors.
There’s a lot of pressure on single-use systems, both in terms of function and material supply. At Cytiva, one of the ways we’ve addressed this pressure is the development of Fortem™ film — designed specifically for single-use bioprocessing applications.
Cytiva’s Fibro technology, known for its increased throughput and productivity in monoclonal antibody purification, is being extended to capture adeno-associated virus (AAV).